Pieris Pharmaceuticals plans to start clinical development of PRS-220 in 2022 for idiopathic pulmonary fibrosis (IPF) — and also…
Articles by Marta Figueiredo, PhD
Adding two broad spectrum antibiotics — co-trimoxazole or doxycycline — to standard care does not significantly delay hospitalization or prolong…
The first healthy volunteer has been dosed in a Phase 1 clinical trial evaluating RXC007, Redx Pharma’s investigational…
Liminal BioSciences is stopping the clinical development of its investigative oral therapy fezagepras (PBI-4050) for idiopathic pulmonary fibrosis (IPF), based…
Note: This story was updated June 11, 2021, to clarify the Chan Zuckerberg Initiative supported the Human Cell Atlas…
Idiopathic pulmonary fibrosis (IPF) patients showing greater changes in blood cell ratios often used as markers of inflammation are…
In a move that refocuses its clinical pipeline, Galapagos is discontinuing the development of GLPG1205, its experimental therapy for…
Outcomes are as poor in people with progressive fibrosing interstitial lung disease (PF-ILD) other than idiopathic pulmonary fibrosis (IPF)…
Scientists at the University of Nottingham, in the U.K., are asking pulmonary fibrosis (PF) patients — many of whom…
Suppressing MDM4, a mechanosensitive protein produced by myofibroblasts — the main drivers of pulmonary fibrosis (PF) — promoted the death…